EX-23.1 3 c0628620exv23w1.htm EX-23.1 CONSENT OF KPMG LLP. EX-23.1 CONSENT OF KPMG LLP.
EXHIBIT 23.1
 
Consent of Independent Registered Public Accounting Firm
 
The Board of Directors
Cumberland Pharmaceuticals Inc.:
 
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” and “Selected Consolidated Financial Data” in the prospectus.
 
KPMG
 
Nashville, Tennessee
July 29, 2009